<DOC>
	<DOCNO>NCT01362621</DOCNO>
	<brief_summary>The study design collect data inadequately control moderate severe allergic asthma subject 6 &lt; 12 year age , manage real-world setting .</brief_summary>
	<brief_title>Observational Epidemiologic Study Disease Course Unmet Needs Children With Symptomatic Moderate Severe Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>Total IgE ≥30 IU ( historical value obtain within 3 month screen visit accept ) . If historic result available , obtain screen visit . Diagnosis asthma least 12 month prior screen visit date , symptom compatible asthma least 12 month diagnosis make within 12 month screen visit Documented sensitivity one perennial aeroallergens evidence positive skin prick test invitro specific IgE test dust mite , cat dander , dog dander cockroach within precede one year screen visit Prescribed inhale corticosteroid least 3 month prior screen ( A ) evidence inadequately control disease either least one list ( B ) OR history asthmarelated exacerbation define ( C ) . [ e.g. , A ( B C ) ] A. Fluticasone DPI &gt; 200 mcg/day equivalent exvalve dose ICS , ≤ 200 mcg fluticasone DPI equivalent plus another daily controller medication ( i.e . LABA , leukotriene antagonist theophylline ) B . At least one follow precede 4 week prior screen visit : average asthma symptom &gt; 2 days/week multiple time day ≤ 2 days/week nighttime awakening ≥ 2 times/month due asthma symptom use SABAs &gt; 2 times/week average limitation activity due asthma spirometric evaluation , FEV1 ≤ 80 % predict , FEV1/FVC ≤ 80 % , peak expiratory flow rate ≤ 80 % personal best C. Minimum 2 asthma exacerbation require oral corticosteroid burst 12 month previous screen visit Subjects currently enrol clinical study therapeutic agent biologic agent participate clinical study therapeutic agent within 30 day Visit 1 biologic agent within 120 day Visit 1 Subjects history prior use omalizumab Subjects severe medical condition view investigator prohibit participation study either impairment ability answer question follow instruction ( e.g. , severe neurological developmental disorder ) Subjects serious respiratoryrelated medical condition allergic asthma , limited , allergic bronchopulmonary aspergillosis , cystic fibrosis bronchiectasis Subjects elevate serum IgE level reason allergy , limited , parasitic infection , hyperimmunoglobulin E syndrome , WiskottAldrich Syndrome Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Allergic asthma</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Exacerbations</keyword>
	<keyword>Perennial aeroallergens</keyword>
	<keyword>Inhaled corticosteroid</keyword>
</DOC>